IDSA Engages House Subcommittee Ahead of Hearing on Antibiotic Resistance (PDF)
In advance of a hearing on federal efforts to address antibiotic resistance, IDSA wrote to leaders of the Subcommittee to urge support for implementation of the National Action Plan for Combating Antibiotic-Resistance Bacteria. The letter placed particular emphasis on antibiotic stewardship, incentives to spur R&D, ID workforce challenges, and the need for increased funding for federal AR programs.
IDSA Zika Vote Statement (PDF)
IDSA urges Congress to pass the strongest emergency bill possible to combat Zika and to reject efforts to fund the Zika response at the expense of equally critical health funding.
IDSA, ASM, and PASCV Letter to FDA on LDTs (PDF)
IDSA, ASM and the Pan-American Society for Clinical Virology urge FDA to consider the vital role of lab developed tests in rapidly diagnosing and appropriately treating infectious diseases.
PACCARB Press Release
Recommendations from the Presidential Advisory Council on Combating Antibiotic Resistant Bacteria reflect IDSA input.
IDSA & HIVMA Engage HHS on Drug Pricing and Innovation
IDSA and HIVMA wrote to HHS Secretary Burwell to distinguish efforts to incentivize development of desperately needed new drugs from recent actions to significantly increase the costs of decades old drugs.
IDSA Provides Testimony to House and Senate Spending Panels on 2017 Budget (PDF)
IDSA provided testimony to the House and Senate subcommittees that oversee spending on health programs. The statement largely focused on federal efforts to combat the Zika virus and antimicrobial resistance.
IDSA Writes to Senate Aging Committee Ahead of Hearing on Drug Pricing Spikes
IDSA wrote to the Senate Special Committee on Aging ahead of a planned hearing on recent drug price spikes. The IDSA letter distinguished efforts to incentivize development of desperately needed new drugs from recent actions to significantly increase the costs of decades old drugs.
IDSA Leads Stakeholders In Support of R&D Tax Credit for Antibiotics and Rapid Diagnostics
Forty groups representing providers, patients, public health and industry joined a letter – circulated by IDSA – supporting the Reinvigorating Antibiotic and Diagnostic Innovation (READI) Act, H.R. 3539.
1 of 8
Zika Virus Infection Related to the Ongoing Investigation of Local Mosquito-borne Zika Virus Transmission in Miami-Dade County, Florida
FDA issues final rule on safety and effectiveness of antibacterial soaps
FDA Advises Testing for Zika Virus in All Donated Blood in the US
August Update: Interim Guidance: Infants with Possible Congenital Zika Virus Infection
July 2016 Safety Labeling Changes posting includes 52 products
FDA approves first generic version of widely used influenza drug
Updated Interim Zika Clinical Guidance for Pregnant Women and Data on Contraceptive Use to Decrease Zika-affected Pregnancies
CDC Update for Guidance for Travel and Testing of Pregnant Women
>> Read More
Infectious Diseases Society of America (IDSA) Vice President Paul Auwaerter, MD, MBA, FIDSA and Treasurer Helen Boucher, MD, FIDSA will join world leaders gathering tomorrow for an historic United Nations (UN) General Assembly meeting on one of the most urgent public health crises facing our world today—antimicrobial resistance (AMR). More than 500 IDSA members with expertise in AMR stand behind Drs. Auwaerter and Boucher on a petition that will be sent to the UN today in support of a coordinated global response to this global threat. Tomorrow’s high level meeting represents a significant opportunity to drive the action needed to effectively stem the tide of AMR.
The Infectious Diseases Society of America (IDSA) is pleased that the Senate Health, Education, Labor and Pensions (HELP)” Committee has scheduled the hearing, “Laboratory Testing in the Era of Precision Medicine,” for September 20, 2016. Infectious diseases (ID) physicians rely upon diagnostics—both laboratory developed tests (LDTs) and commercial tests—to identify infecting pathogens and their antimicrobial susceptibility and to monitor response to treatment.
All patients beginning hepatitis C (HCV) treatment using direct acting antiviral (DAA) therapies should be assessed for hepatitis B (HBV), according the American Association for the Study of Liver Diseases/Infectious Diseases Society of America Guidance Panel, which provides up-to-date guidance on the treatment of hepatitis C on its website, HCVguidelines.org.
>>Read More From the PresidentDon't Miss These IDSA Guidelines UpdatesIDSA Honors 111 Distinguished Physicians, Scientists with FIDSAIDWeek 2016: Not-to-Miss Sessions Featuring the Latest on the Zika OutbreakJournal Club
Tuberculosis (TB) is a leading killer of people with HIV, and providing therapy for both illnesses simultaneously saves lives - according to new guidelines on the treatment of drug-susceptible TB developed jointly by the American Thoracic Society (ATS), Centers for Disease Control and Prevention (CDC) and Infectious Diseases Society of America (IDSA). Treatment of TB in the presence of HIV infection is one of several special situations addressed in the new guidelines, published today in the journal Clinical Infectious Diseases.
Florida health officials and the Centers for Disease Control and Prevention (CDC) today confirmed local transmission of the Zika virus in a specific area of Dade and Broward Counties in Florida, emphasizing the need for robust, ongoing Zika surveillance and response preparedness wherever Zika-transmitting mosquitos are found in the US. Infectious diseases physicians are urging the public to take measures to protect themselves from contracting the virus while also urging Congress to provide the funding necessary for an appropriate public health response.
Early diagnosis ensures the best management and reduces unneeded tests and treatment, note updated guidelines released by the Infectious Diseases Society of America (IDSA) and published in the journal Clinical Infectious Disease.
1 of 7
1300 Wilson Boulevard Suite 300 Arlington, VA 22209 | Phone: (703) 299-0200 | Fax: (703) 299-0204
| HIVMA | Contact Us
© Copyright IDSA 2016 Infectious Diseases Society of America